Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Seven deaths possibly linked to malfunctioning glucose monitors - 2SF Chinatown's historic Empress of China building being revived into cultural campus
- 3How grandchildren are stepping up to fill the caregiver gap
- 4Rescuers give up hope for the humpback whale stranded in the Baltic Sea
- 5At least 30 killed in attack on Nigeria village
- This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- China resumes flights to North Korea after a six-year pause
- Limited Rain Chances in Brazil Boost Coffee Prices
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
- Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- Two Endangered Bengal Tiger Cubs Die Days Apart at Zoo After Contracting Virus
- New Cheetos and Doritos will be free of artificial dyes
- Foreign journalist kidnapped in Iraq: Interior Ministry
- New research reveals urban raccoons across the US show early signs of domestication
